- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04584528
Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease (ALIGN)
Improving SCD Care Using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North Carolina
Study Overview
Status
Intervention / Treatment
Detailed Description
The study aims are as follows:
Aim 1: Assess the overall effectiveness of EHR-embedded IPPs on improving patient and provider outcomes associated with pain treatment in the adult ED setting. We will evaluate the effectiveness of the intervention on both patients and providers using a pre-post study design.
Sub-aim 1.a. To examine effectiveness of the EHR-embedded IPP on improving patients' perceived quality of ED pain treatment. We hypothesize that among enrolled patients with at least one ED VOE visit during the intervention period, the perceived quality of ED pain treatment will increase by 0.5 standard deviation (primary outcome) after an ED VOE visit when compared with the last ED VOE visits made by these patients within 90 days before enrollment. We will measure change pre- and post-intervention in secondary patient outcomes, including hospital admission rate within 12 months, ED VOE revisit rate, ED VOE readmission rate, and time to first dosage of pain medication provided in the ED.
Sub-aim 1.b. To examine the effectiveness of the EHR-embedded IPP on improving providers' self-efficacy in treating pain for patients with SCD and perceived quality of ED pain treatment. We hypothesize that the intervention will increase providers' self-efficacy in treating VOEs and managing pain for patients with SCD when compared with self-efficacy before the intervention. We will also explore the effect of the intervention on ED providers' perceived quality of ED pain treatment.
Aim 2: Assess the reach, adoption, implementation, and maintenance of the EHR-embedded IPP components and implementation strategies at each participating site. We will use the RE-AIM framework to evaluate intervention outcomes in addition to intervention effectiveness.
Sub-aim 2.a. To assess the reach of the EHR-embedded IPP. We will assess the reach of the intervention at the patient level by examining the proportion of patients enrolled in the study among all patients the team has reached out to recruit, and at the clinic level by examining the proportion of clinics participating in the intervention.
Sub-aim 2.b. To assess the adoption and implementation of the EHR-embedded IPP and track implementation strategies adopted by each site. We will assess the adoption of the intervention by examining characteristics of individual EDs that participate relative to the number of individual EDs affiliated with each study site who could have been recruited. We will assess implementation fidelity and outcomes, such as the proportion of eligible hematologists and nurse practitioners who receive IPP training, number of IPPs written and included in the EHR, required and optional intervention elements that are implemented as planned, IPP use by patients and providers, provider IPP adherence, and patients' and providers' perceived ease of use of the IPPs. We will track and report strategies used by participating sites through both quantitative data collection and qualitative interviews.
Sub-aim 2.c. To assess the intent to continue using the IPP from a multi-stakeholder perspective. We will assess patients' and providers' intent to continue using the IPP during the implementation period. At the end of the intervention, we will assess ED administrators' intent to continue using the IPP.
Aim 3: Assess organizational readiness at the beginning of the implementation and barriers and facilitators to the use of EHR-embedded IPPs. We will perform a Readiness Assessment to measure organization- and staff-level readiness at the beginning of the intervention to inform the selection and adaptation of implementation strategies. We will assess facilitators and barriers in adopting and implementing the IPPs from multiple stakeholder perspectives: patients, providers, and ED administrators.
Embedding IPPs in the EHR that are accessible to both ED providers and patients is a promising intervention to support the NHLBI evidence-based recommendations to guide treatment of VOE in the ED setting and improve quality of pain treatment in the ED and better patient outcomes. If EHR-embedded IPPs implemented and evaluated in this study show preliminary effectiveness, they could be scaled up within SCDIC Centers and expanded to other institutions outside the SCDIC. The results of this proposed study will accelerate the uptake of the NHLBI recommendation and establish standardized treatment in EDs for patients with SCD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94609
- University of California San Francisco
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Georgia Regents University
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude's
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patient Inclusion Criteria:
- Age 18 years up to and including 45 years
- English speaking
- Confirmed SCD diagnoses . Confirmed is defined as supported by documentation in the medical record of a positive test for one of the following : Hb SS, Hb SC, Hb S -thalassemia, Hb SO, Hb SD, Hb SG, Hb SE, or Hb SF.
- Access to a cellular/mobile smart phone with access to text messaging (either Android or iPhone acceptable) .
- At least one Vaso-Occlusive Episode (VOE) visit to participating site Emergency Department (ED) the past 90 days from enrollment
- At least one visit at the study site sickle cell disease clinic within the past 12 months
- Willing and cognitively able to give informed consent
Patient Exclusion criteria:
- Patient's sickle cell provider states patient should not have a protocol or should not be administered opioids
Provider Inclusion Criteria:
- Provides pain treatment in one of the participating study Emergency Departments for a patient participant with a qualified ED visit .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: EHR-embedded Individualized Pain Plan (IPP)
The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
|
The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:
If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Patient-perceived quality of ED pain treatment.
Time Frame: Baseline, 96 hours
|
Three questions from the Adult Sickle Cell Quality of Life Measure (ASCQ-Me) and Quality of Care (QOC) measure will be used to measure the patient perceived quality of ED pain treatment
|
Baseline, 96 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ED revisit rate as measured by EHR retrieval
Time Frame: Day 7
|
Day 7
|
ED revisit rate as measured by EHR retrieval
Time Frame: Day 30
|
Day 30
|
Hospital readmission rate measured by EHR retrieval
Time Frame: Day 7
|
Day 7
|
Hospital readmission rate measured by EHR retrieval
Time Frame: Day 30
|
Day 30
|
Time to first dose of pain medication measured by EHR retrieval
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00073506_1
- 5U01HL133964-05 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Diseases
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
Clinical Trials on Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
-
University of North Carolina, Chapel HillMayo Clinic; National Library of Medicine (NLM); University of Pittsburgh Medical... and other collaboratorsRecruitingCritical Care | Usability | Electronic Health Records | Information Seeking BehaviorUnited States
-
Weill Medical College of Cornell UniversityThe Commonwealth Fund; New York State Department of Health; Taconic Health Information... and other collaboratorsCompletedElectronic Health Records | Quality of Health CareUnited States
-
Scott C. Woller, MDJanssen PharmaceuticalsNot yet recruitingDeep Vein Thrombosis | Hospitalism | Venous Thromboembolic Disease | Pulmonary Embolism and ThrombosisUnited States
-
Children's National Research InstituteNot yet recruitingPain | Fractures, Bone | Appendicitis | Bias, Racial
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingBlood Pressure | Medication AdherenceUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingSmoking CessationUnited States
-
University of Colorado, DenverAgency for Healthcare Research and Quality (AHRQ)Completed
-
Denver Health and Hospital AuthorityPatient-Centered Outcomes Research Institute; Mayo Clinic; Intermountain Health... and other collaboratorsNot yet recruitingPediatric Infectious Disease | Acute Otitis Media | Ear Infection
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
University of Southern DenmarkOdense University Hospital; Holbaek Sygehus; Aalborg University; Steno Diabetes... and other collaboratorsNot yet recruiting